Research Desk Line-up: Actuant Post Earnings Coverage
LONDON, UK / ACCESSWIRE / June 28, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Hebron Technology Co., Ltd (NASDAQ: HEBT), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=HEBT. The Company, which is a developer, manufacturer, and installer of valves and pipe fittings, announced on June 26, 2017, that it has signed a framework cooperation agreement to form a joint venture with Research and Product Complex BioPromin Ltd, a Ukraine-based Company specializing in noninvasive blood analyzing medical devices. For immediate access to our complimentary reports, including today's coverage, register for free now at: http://protraderdaily.com/register/.
Discover more of our free reports coverage from other companies within the Diversified Machinery industry. Pro-TD has currently selected Actuant Corporation (NYSE: ATU) for due-diligence and potential coverage as the Company announced on June 21, 2017, its financial results for Q3 which ended on May 31, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Actuant when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on HEBT; also brushing on ATU. Go directly to your stock of interest and access today's free coverage at:
Subject to the terms of the agreement executed on June 16, 2017, both Hebron and BioPromin have agreed to develop, manufacture, and market BioPromin's proprietary noninvasive blood analyzing devices in China. The joint venture will be based in Konggang New Area, Longgang District, Wenzhou City, Zhejiang Province, with a registered capital of $5 million and a total investment of up to $50 million. According to the announcement, Hebron will own 80% of the Joint Venture, where BioPromin will hold the remaining 20% of the venture and the right of first refusal to acquire an additional 5% ownership in the venture from Hebron.
Hebron views this agreement as a step to penetrate into the China's huge medical devices industry. Through the joint venture, the Company plans to integrate deep ties to the pharmaceutical industry and strong capabilities in manufacturing and marketing with BioPromin's innovative blood analyzing techniques. Hebron plans to bring BioPromin's clinically-proven blood analyzer products to the Chinese market, through this step.
BioPromin's portfolio includes products like Automatic Noninvasive Express Screening Analyzer ("ANESA"), Noninvasive Hemogram Analyzer AMP, Low-Intensity Microwave and Decimeter Wave Therapy Apparatus "BIOL", and Star device.
Hebron Technology deals in the development, manufacture, and delivery of customized installation of valves, and pipe fittings. It additionally offers pipeline design, installation, construction, and ongoing maintenance services. For the six month period, ended December 31, 2016, the Company reported that its net revenues surged 17.9% to $16.4 million, with revenues from installation services and fluid equipment sales increasing 19.7% and 5.9% respectively.
Prior to the announcement, on March 10, 2017, the Company announced that it has entered into a non-binding Letter of Intent (LOI) pursuant to which Hebron acquired a majority equity interest in Shanghai Xinxiao Co., Ltd. Xinxiao currently operates one of the largest marketplaces for equipment and products used in the pharmaceutical, biological, chemical, food and beverage, and environmental industries. Hebron viewed this agreement as a definitive plan to expand its ecommerce business while leveraging the extensive database and strong relationships with leading Companies in the particular industry.
On May 24, 2017, Hebron Technology announced that it has won a bid on the design and implementation of an oil-free compressed air pipe project at a pharmaceutical production facility, currently owned by Tianjin Chase Sun Pharmaceutical Co., Ltd. Chase Sun currently operates through its 6,000 employees and reported net annual sales of RMB 3.9 billion. This project was viewed as the development of Company's pharmaceutical product portfolio, as per the demand pertaining from the leading Pharmaceutical Companies in China. Hebron plans to leverage Chase Sun's expansion strategy to enhance the scale of its business and establish itself as the leading product manufacturer and deliver in the country.
Last Close Stock Review
At the close of trading session on Tuesday, June 27, 2017, Hebron Technology's stock price rose 3.91% to end the day at $2.92. A total volume of 33.42 thousand shares were exchanged during the session. The Company's shares are trading at a PE ratio of 5.92. At Tuesday's closing price, the stock's net capitalization stands at $44.03 million.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily